10-Q: Vivos Therapeutics Reports Wider Losses Amid Strategic Pivot

Vivos Therapeutics, Inc. reported a significant increase in net losses and a going concern warning despite revenue growth driven by its new acquisition-focused business model.

Summary

• Total revenue increased by 76% to $6.8 million for the three months ended September 30, 2025, compared to $3.9 million in the prior year, primarily due to the acquisition of The Sleep Center of Nevada (SCN).
• Net loss widened to $5.4 million for the three months ended September 30, 2025, from $2.6 million in the same period last year.
• For the nine months ended September 30, 2025, total revenue grew 20% to $13.6 million, but net loss increased to $14.3 million from $8.3 million in the prior year period.
• The company acquired The Sleep Center of Nevada (SCN) on June 10, 2025, for $6.0 million in cash, 607,287 shares of common stock (valued at $1.5 million), and assumed liabilities, with a potential $1.5 million contingent earn-out.
• SCN contributed $2.2 million in sleep testing services revenue and $1.3 million in treatment center revenue for the three months ended September 30, 2025.
• Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, from $6.3 million at December 31, 2024.
• Total liabilities surged to $23.1 million as of September 30, 2025, from $7.3 million at December 31, 2024, largely due to $8.3 million in new senior secured debt incurred for the SCN acquisition.
• The company raised $3.7 million in gross proceeds from a private placement offering with V-Co Investors 2 LLC in June 2025.
• An At-The-Market (ATM) equity offering sold 762,070 shares for $2.4 million net proceeds in Q3 2025, with $3.3 million remaining available as of September 30, 2025, and an additional $2.1 million raised in October/November 2025.
• The company faces substantial doubt about its ability to continue as a going concern without additional financing.
• A confidential settlement has been agreed upon in principle for the ongoing Ortho-Tain litigation as of October 23, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including a substantial increase in net losses, a sharp decline in cash, and a 'going concern' warning. While revenue growth from the new business model is positive, the associated increase in debt and operating expenses, coupled with unproven aspects of the new strategy and Nasdaq delisting risk, indicate a highly precarious financial position. The legal settlement is a minor positive against a backdrop of major financial challenges.

Positives

• Total revenue increased significantly by 76% for the three months and 20% for the nine months ended September 30, 2025, driven by the new business model.
• Service revenue, particularly from sleep testing and treatment centers (SCN), saw substantial growth, with $2.2 million from sleep testing and $1.3 million from treatment centers in Q3 2025.
• The SCN acquisition represents a successful execution of the new strategic pivot towards direct patient care and higher-margin revenue streams.
• Patient demand at SCN locations is exceeding current capacity, indicating strong market interest in Vivos treatment options.
• The company has successfully raised capital through debt and equity financings to support the SCN acquisition and working capital.
• An agreement on principal terms for a confidential settlement in the Ortho-Tain litigation was reached, potentially resolving long-standing legal disputes.

Negatives

• Net loss significantly widened to $5.4 million in Q3 2025 from $2.6 million in Q3 2024, and to $14.3 million for the nine months ended September 30, 2025, from $8.3 million in the prior year period.
• The company has an accumulated deficit of approximately $118.5 million as of September 30, 2025.
• Cash and cash equivalents decreased by over 50% from $6.260 million at December 31, 2024, to $3.087 million at September 30, 2025.
• Total liabilities increased substantially to $23.1 million, including $8.3 million in new senior secured debt, raising concerns about debt servicing capacity.
• Total stockholders' equity decreased from $7.954 million to $2.532 million, nearing Nasdaq's minimum equity requirement.
• Gross profit margin decreased to 58% in Q3 2025 from 60% in Q3 2024, and to 55% for the nine months from 61% in the prior year, due to higher cost of sales relative to revenue.
• General and administrative expenses increased significantly by 76% in Q3 2025 and 42% for the nine months, largely due to SCN integration and operational costs.
• The company explicitly states 'substantial doubt regarding the Company’s ability to continue as a going concern' without additional financing.
• Revenue from the initial Rebis Health strategic alliance did not meet expectations due to delays beyond the company's control.

Risks

• The new sales, marketing, and distribution model, including the SCN acquisition and future alliances, is unproven and may not yield anticipated benefits.
• Integration of SCN's operations may be more difficult, costly, or time-consuming than expected, potentially disrupting business and affecting patient/employee relationships.
• Contractual arrangements with SCN physicians may be found to violate state corporate practice of medicine (CPM) laws or fee-splitting laws, leading to restructuring or termination of arrangements, penalties, and loss of revenue.
• Increased exposure to lawsuits, governmental investigations, and audits (e.g., billing practices) due to direct patient care model.
• Changes in private insurance, Medicare, Medicaid, or other government-based program payment rates could materially adversely affect business and financial results.
• Inability to recruit qualified talent and manage labor costs or shortages for Sleep Optimization (SO) teams could increase operating costs and disrupt business operations.
• Trade policy and tariff risks, particularly for products or components manufactured outside the United States, could impact sourcing strategy and competitiveness.
• Inflationary pressures may continue to increase costs for the company and its suppliers, potentially requiring further price adjustments that could affect sales or demand.
• Federal Reserve's response to inflation (elevated interest rates) could negatively impact capital markets and the company's access to capital.
• Supply chain challenges, although not significant recently, could emerge in future periods.
• Geopolitical conflicts (War in Ukraine, Middle East hostilities) could lead to economic recession or depression, decreasing demand for products and making capital raising more difficult.
• Risk of Nasdaq delisting due to failure to maintain the $2.5 million minimum stockholders' equity requirement.

Future Outlook

The company is fully engaged in maximizing the SCN opportunity, expecting to increase diagnostic sleep testing and Vivos treatment center revenue in Q4 2025 and into 2026. It plans to deploy additional Sleep Optimization (SO) teams to meet patient demand, with 4.5 SO teams expected by the end of Q1 2026. The company anticipates each SO team could generate over $500,000 per month in collections with contribution margins above 50% once fully operational. Lessons learned from SCN integration will be applied to future acquisitions or collaborations. A new management services entity model is being implemented, with the first location in Auburn Hills, Michigan, expected to open in early December 2025. The company continues to explore additional acquisition targets and strategic affiliations to drive future accretive growth. VIP enrollment revenue is expected to cease by the end of 2026 as the company pivots away from its legacy model.

Management Comments

• "We originally expected our Strategic Alliance Agreement (SAA) with Rebis Health in Colorado entered into in June 2024 to increase patient volume, drive top line revenue and lower customer acquisition costs and overhead. However, due to ongoing delays at Rebis Health that have been beyond our control, we are currently re-evaluating and lowering our revenue expectations under the SAA and are seeking to make other acquisitions or enter into other strategic alliances."
• "We expect a short-term drop in sales and an increase in costs as we executed on our business model pivot. This trend began to shift materially in the quarter ended September 30, 2025 as we experienced our first full quarter of SCN operations and resulting in increases in revenue."
• "Based on the current volume of OSA patient demand, we believe the current markets served by SCN could support up to eight SO teams, and potentially more if certain planned growth initiatives meet expectations."
• "Based on our experience to date, we believe our limiting constraints for near-term revenue growth at SCN are (1) physical space to see an optimal number of patients; (2) provider and staff recruiting, training, and onboarding; and (3) customary issues with third party provider credentialing."
• "We expect the current expansion at one facility and relocation of a second facility, coupled with the additional deployments of the two new SO teams by year-end 2025, will help reduce the backlog of patients seeking treatment. However, we do not believe we will be able to fully meet current demand until additional SO teams are fully deployed during 2026."
• "Our initial average case revenue and acceptance rate for Vivos treatment at SCN to date suggest that each SO team could potentially generate collections in excess of $500,000 per month, net of adjustments, with contribution margins above 50%."

Industry Context

Vivos Therapeutics is pivoting its business model in the obstructive sleep apnea (OSA) treatment market, moving from a dentist-centric VIP training model to a direct patient care model through acquisitions and strategic alliances with sleep centers. This shift aims to capture higher-margin diagnostic and treatment revenues directly. The OSA market is significant, with a demand for non-CPAP, non-surgical solutions. The company's strategy to acquire and manage sleep centers, like SCN, aligns with a trend towards integrated healthcare delivery, where companies seek to control more of the patient journey from diagnosis to treatment. The challenges faced, such as provider training, insurance reimbursement, and capacity constraints, are common in scaling medical technology and service offerings in a regulated healthcare environment. The focus on proprietary oral appliances and therapeutic treatments positions Vivos against traditional CPAP therapies and other oral appliance providers, emphasizing a potentially curative, rather-than-palliative, approach.

Comparison to Industry Standards

• The Vivos Method's claim of potentially reversing OSA symptoms in up to 80% of patients in a small subset of a study, and not needing lifetime intervention unlike CPAP and neuro-stimulation implants, positions it as a potentially superior alternative to current industry standards.
• The company's shift to acquiring and operating sleep centers, like SCN, is a strategic move to gain more control over the patient funnel and capture a larger share of the treatment revenue, a model that can be compared to integrated delivery networks or dental service organizations (DSOs) in other healthcare sectors, though specific comparable companies in the OSA space using this exact model are not detailed in the filing.
• The reported average case revenue and acceptance rate for Vivos treatment at SCN, suggesting each SO team could generate collections in excess of $500,000 per month with contribution margins above 50%, provides an internal benchmark for the new model's potential, but lacks external industry benchmarks for direct comparison.

Corporate Governance

Legal Proceedings

• The company filed suit against Ortho-Tain, Inc. in the U.S. District Court for the District of Colorado on June 5, 2020, alleging false, threatening, and defamatory statements, interference with business relationships, harm to reputation, and loss of goodwill. The company seeks permanent injunctive relief, declaratory relief, and monetary damages.
• Ortho-Tain, Inc. filed a complaint in the U.S. District Court for the Northern District of Illinois on July 22, 2020, against the company and others, alleging violation of the Lanham Act, civil conspiracy, and breach of contract. This case was stayed but the stay was lifted on March 2, 2023.
• On October 23, 2025, the parties in both the Colorado and Illinois Ortho-Tain cases attended mediation and agreed upon principal terms of a confidential settlement, with definitive agreement negotiations ongoing.

Related Party Transactions

• On June 9, 2025, the company entered into a Securities Purchase Agreement with V-Co Investors 2 LLC, an affiliate of New Seneca Partners Inc. (a significant investor), for a private placement offering of common stock and warrants, generating $3.7 million in gross proceeds.
• Dr. Prabhu, SCN's principal owner, entered into a physician employment agreement with SCN (or SCN affiliated companies) with an annual compensation of $400,000 and bonus incentives, and holds a board observation right with the company.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises (debt and equity), increased net losses, and a 'going concern' warning. The stock price is highly susceptible to fluctuations due to unproven business model and financial instability. Potential for long-term value if the new model succeeds, but high short-term risk.
• **Employees:** The business model pivot involves reducing sales personnel in the legacy VIP model and hiring/training new Sleep Optimization (SO) teams for the direct patient care model. This creates job shifts and new opportunities but also potential for disruption and increased labor costs.
• **Customers (Patients):** The new direct patient care model through acquired sleep centers aims to provide better access to Vivos products and services, potentially improving treatment options for OSA patients. However, initial capacity constraints at SCN may lead to delays in appointments.
• **Dentists/Healthcare Providers:** The legacy VIP model is being phased out, impacting dentists who relied on it. The new model focuses on employing or collaborating with medical sleep specialists and nurse practitioners, creating new roles and training requirements for these professionals.
• **Creditors:** Streeterville Capital, LLC, as a senior secured lender, has significant claims against the company's assets, particularly AIM's assets and membership interests, increasing risk for other creditors given the company's financial condition and 'going concern' doubt.
• **Suppliers:** The company relies on a few key suppliers (five suppliers account for 57% of purchases), making it vulnerable to supply chain disruptions or changes in supplier relationships.

Next Steps

• Finalize negotiation of a definitive settlement agreement for the Ortho-Tain litigation.
• Continue to integrate SCN operations, including deploying additional Sleep Optimization (SO) teams to meet patient demand.
• Ramp up systems and operations at SCN to process and treat more patients, aiming for 4.5 SO teams by the end of Q1 2026.
• Expand diagnostic and treatment services at SCN, establish a pediatric OSA program, and collaborate with specialty medical groups.
• Open the MISleep Solution LLC facility in Auburn Hills, Michigan, in early December 2025 and deploy a complete SO team.
• Continue active discussions with potential acquisition targets and strategic sleep center affiliations.
• Monitor U.S. trade policy and adjust manufacturing and sourcing strategy as needed to manage tariff risks.
• Revisit standard pricing for appliance products in 2026 to manage inflationary pressures.
• Review all options to obtain additional financing to fund operations until positive cash flow is attained.
• Work diligently to ensure continued compliance with Nasdaq's minimum stockholders' equity requirement.

Key Dates

Recommendation

Despite revenue growth driven by the SCN acquisition, the company's financial health has significantly deteriorated, evidenced by a substantial increase in net losses, a sharp decline in cash, and a significant increase in total liabilities. The explicit 'substantial doubt regarding the Company’s ability to continue as a going concern' is a critical red flag for any seasoned investor. While the new business model shows potential, it is unproven, faces integration challenges, and requires ongoing capital raises, which further dilute existing shareholders. The current financial instability and high operational risks outweigh the speculative upside, making it a high-risk investment. A seasoned investor would likely recommend selling to mitigate exposure to a company facing such severe liquidity and solvency concerns.

Keywords

Obstructive Sleep Apnea, OSA, Dentofacial Abnormalities, Oral Appliances, Medical Technology, Sleep Centers, SCN Acquisition, Going Concern, SEC Filing, 10-Q, Healthcare, Medical Devices, Corporate Practice of Medicine, Capital Raise, Nasdaq